Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

Moussa, Charbel; Hebron, Michaeline; Huang, Xu; Ahn, Jaeil; Rissman, Robert A.; Aisen, Paul S.; Turner, R. Scott

doi:10.1186/s12974-016-0779-0

Cited by 582 publications

(436 citation statements)

References 52 publications

Supporting

Mentioning

398

Contrasting

Unclassified

Order By: Relevance

“…This compound, together with its dimer trans ‐ε‐viniferin, may improve cognition by modulating GABA A R‐induced currents (Moussa et al . ). In the study performed by Moussa et al .…”

Section: Allosteric Modulators Of Gabaa Receptorsmentioning

confidence: 97%

The GABAergic system as a therapeutic target for Alzheimer's disease

Guzmán

Vinnakota

Govindpani

et al. 2018

Journal of Neurochemistry

131

View full text Add to dashboard Cite

Glutamatergic and cholinergic dysfunction are well-attested features of Alzheimer's disease (AD), progressing with other pathological indices of the disorder and exacerbating neuronal and network dysfunction. However, relatively little attention has been paid to the inhibitory component of the excitatory/inhibitory (E/I) network, particularly dysfunction in the gamma-aminobutyric acid (GABA) signaling system. There is growing evidence in support of GABAergic remodeling in the AD brain, potentially beginning in early stages of disease pathogenesis, and this could thus be a valid molecular target for drug development and pharmacological therapies. Several GABAergic drugs have been tested for efficacy in attenuating or reversing various features and symptoms of AD, and this could represent a novel path by which we might address the growing need for more effective and benign therapies.

show abstract

“…This compound, together with its dimer trans ‐ε‐viniferin, may improve cognition by modulating GABA A R‐induced currents (Moussa et al . ). In the study performed by Moussa et al .…”

Section: Allosteric Modulators Of Gabaa Receptorsmentioning

confidence: 97%

The GABAergic system as a therapeutic target for Alzheimer's disease

Guzmán

Vinnakota

Govindpani

et al. 2018

Journal of Neurochemistry

131

View full text Add to dashboard Cite

show abstract

“…Recently, resveratrol has gained more interest to treat AD due to its greater neuroprotective effect, and many studies confirmed that resveratrol treatment significantly improved the cognition and biochemical parameters. [114][115][116][117][118][119][120][121][122][123] Recently, resveratrol-loaded SLN was studied for its bioavailability and brain delivery. Resveratrol was efficiently delivered to the brain and exhibited its potential bioactivity.…”

Section: Anti-alzheimer's Effectmentioning

confidence: 99%

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Ganesan

Ramalingam

Karthivashan

et al. 2018

IJN

135

View full text Add to dashboard Cite

Solid lipid nanoparticle (SLN) delivery systems have a wide applicability in the delivery of phyto-bioactive compounds to treat various chronic diseases, including diabetes, cancer, obesity and neurodegenerative diseases. The multiple benefits of SLN delivery include improved stability, smaller particle size, leaching prevention and enhanced lymphatic uptake of the bioactive compounds through oral delivery. However, the burst release makes the SLN delivery systems inadequate for the oral delivery of various phyto-bioactive compounds that can treat such chronic diseases. Recently, the surface-modified SLN (SMSLN) was observed to overcome this limitation for oral delivery of phyto-bioactive compounds, and there is growing evidence of an enhanced uptake of curcumin delivered orally via SMSLNs in the brain. This review focuses on different SLN and SMSLN systems that are useful for oral delivery of phyto-bioactive compounds to treat various chronic diseases.

show abstract

“…Taken together these observations suggest that resveratrol may slow down a cognitive decline through a coordinated peripheral and central immune response. These encouraging results are a starting point to further validating the neuroprotective effects of resveratrol (Moussa et al, ).…”

Section: Polyphenol Neuroprotective Potentialmentioning

confidence: 75%

Adult‐onset brain tumors and neurodegeneration: Are polyphenols protective?

Squillaro

Schettino

Sampaolo

et al. 2017

Journal Cellular Physiology

View full text Add to dashboard Cite

Aging is a primary risk factor for both neurodegenerative disorders (NDs) and tumors such as adult-onset brain tumors. Since NDs and tumors are severe, disabling, progressive and often incurable conditions, they represent a pressing problem in terms of human suffering and economic costs to the healthcare systems. The current challenge for physicians and researchers is to develop new therapeutic strategies in both areas to improve the patients' quality of life. In addition to genetics and environmental stressors, the increase in cellular oxidative stress as one of the potential common etiologies has been reported for both disorders. Recently, the scientific community has focused on the beneficial effects of dietary antioxidant classes, known as nutraceuticals, such as carotenoids, vitamins, and polyphenols. Among these compounds, polyphenols are considered to be one of the most bioactive agents in neurodegeneration and tumor prevention. Despite the beneficial activity of polyphenols, their poor bioavailability and inefficient delivery systems are the main factors limiting their use in medicine and functional food. The development of polymeric nanoparticle-based delivery systems able to encapsulate and preserve polyphenolic compounds may represent a promising tool to enhance their stability, solubility, and cell membrane permeation. In the present review we provide an overview of the main polyphenolic compounds used for ND and brain tumor prevention and treatment that explores their mechanisms of action, recent clinical findings and principal factors limiting their application in medicine.

show abstract

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

Cited by 582 publications

References 52 publications

The GABAergic system as a therapeutic target for Alzheimer's disease

The GABAergic system as a therapeutic target for Alzheimer's disease

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Adult‐onset brain tumors and neurodegeneration: Are polyphenols protective?

Contact Info

Product

Resources

About